Therapeutic effectiveness of slow-release PLGA-oxaliplatin microsphere on human colorectal tumor-bearing mice

Anti-Cancer Drugs

Volumn 21, Issue 6, 2010, Pages 600-608

  Li, Jing Quan ^a   Wang, Shi Liang ^c   Xu, Fei ^a   Liu, Zhao Yang ^b   Li, Rong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c HEFEI UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Colorectal cancer; Microsphere; Nude mice; Oxaliplatin; Slow release

Indexed keywords

CYCLINE; MICROSPHERE; OXALIPLATIN; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CANCER INHIBITION; CANCER RECURRENCE; COLON RESECTION; COLORECTAL TUMOR; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SLOW DRUG RELEASE; SPRAY DRYING; THERAPY EFFECT; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSPHERES; ORGANOPLATINUM COMPOUNDS; POLYGLYCOLIC ACID; TREATMENT OUTCOME;

EID: 77953521575     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283393004     Document Type: Article

References (18)

1. American Cancer Society. Cancer facts & figures 2008. Atlanta: American Cancer Society; 2008.
2. Moriya Y. Treatment strategy for locally recurrent rectal cancer. Jpn J Clin Oncol 2006; 36:127-131.
3. Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, van den Brule AJ, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007; 13 (22 Pt 1):6617-6623.
4. Bosch Roig CE, Roselló -Sastre E, Alonso Hernández S, Almenar Cubells D, Grau Cardona E, Camarasa Lillo N, et al. Prognostic value of the detection of lymph node micrometastases in colon cancer. Clin Transl Oncol 2008; 10:572-578.
5. Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Có ppola F, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001; 37:1006-1013.
6. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008; 12:iii-iix. xi-162.
7. Firth G, Oliver AS, McKeran RO. Studies on the intracerebral injection of bleomycin free and entrapped within liposomes in the rat. J Neurol Neurosurg Psychiatry 1984; 47:585-589.
8. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148:269-275.
9. Withrow SJ, Liptak JM, Straw RC, Dernell WS, Jameson VJ, Powers BE, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004; 11:705-713.
10. Okino H, Maeyama R, Manabe T, Matsuda T, Tanaka M. Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice. Clin Cancer Res 2003; 9:5786-5793.
11. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomaterials Sci - Polymer Edition 2006; 17:247-289.
12. Gutman RL, Peacock G, Lu DR. Targeted drug delivery for brain cancer treatment. J Control Release 2000; 65:31-41.
13. Kornmann M, Butzer U, Blatter J, Beger HG, Link KH. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 2000; 26:583-587.
14. Li J-Q, Zhao P,Wang S-L, Tang Z-Q, Yang M, Liu Z-Y, et al. Phamacokinetical study of interstitial chemotherapy with PLGA-gemcitabine microsphere. Oncology Progress 2008; 6:191-196.
15. Howells LM, Mitra A, Manson MM. Comparison of oxaliplatin- and curcuminmediated antiproliferative effects in colorectal cell lines. Int J Cancer 2007; 121:175-183.
16. Shen Y, Wang J, Yang T, Li Y, Jiang W, Guan Z, et al. Platinums sensitize human epithelial tumor cells to lymphotoxin alpha by inhibiting NFkappaB-dependent transcription. Cancer Biol Ther 2008; 7:1407-1414.
17. Gamelin L, Boisdron-Celle M, Delva R, Gué rin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10 (12 Pt 1):4055-4061.
18. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.